1Reeder TL,Bailey RJ,Dewald GW,et al.Both B and T lymphocytes may be clonally involved in myelofibrosis with myelofibrosis with myeloid metaplasia[J].Blood,2003,101 (5):1981-1983.
2Mesa RA,Hanson CA,Rajkumar SV,et al.Evaluation and clinical correlations of bone marrow angiogenesis in myelofibrosis with myeloid metaplasia[J].Blood,2000,96 (10):3374 -3380.
3Zweegman S,Veenhof MA,Huijgens PC,et al.Regulation of megakaryocytopoiesis in an in vitro stroma model:preferential adhesion of megakaryocytic progenitors and subsequent inhibition of maturation[J].Exp Hematol,2000,28(4):401-410.
4Joseph J,Mazza MD.Manual of clinical hematology[M].3rd edition.Lippincott:Williams& Wilkins,2002:195-204.
5Tlhele J,Kvasnicka HM,Schmitt-Graeff A,et al.Effects of interferon and hydroxyurea on bone marrow fibrosis in chronic myelogenous leukemia:a comparative retrospective muticentre histological and clinical study[J].Br J Hematol,2000,108 (1):64-71.
6Martyre MC.TGF-β and megakaryocytes in the pathogenesis of myeloproliferative disorders[J].Leuk Lymphoma,1995,20(1-2):39-44.
7Castro-Malaspina H,Gay RE,Jhanwar SC,et al.Characteristics of bone marrow fibroblast colony-forming cells(CFU-F) and their progeny in patients with myeloproliferative disorders[J].Blood,1982,59(5):1046-1054.
8Castro-Malaspina H,Rabellino EM,Yen A,et al.Human megakaryocyte stimulation of proliferation of bone marrow fibroblasts[J].Blood,1981,57(4):781-787.
10Buschle M,Janssen JWG,Drexler H,et al.Evidence for pluripotent stem cell origin of idiopathic myelofibrosis:clonal analysis of a case characterized by an N-ras gene mutation[J].Leukemia,1988,2:658-660.
二级参考文献60
1[1]张之南,主编.血液病诊断及疗效标准.第2版.北京:科学出版社,1999.373-379.
2[2]Mesa RA, Rajkumar SV, Hanson CA, et al. Evaluation and clinical correlation of microvessel density in myelofibrosis with myeloid metaplasia. Blood, 1999, 94(Suppl 1 ): 115a.
3[3]Martyre MC, Le Bousse-Kerdiles MC, Romquin N, et al. Elevated levels of basic fibroblast growth factor in megakarocytes and platelets from patients with idiopathic myelofibrosis. Br J Haematol, 1997, 97(2):441-448.
4[4]Martyre MC, Romquin N, Le Bousse-Kerdiles MC, et al. Transforming growth factor-13 and megakaryocytes in the pathogenesis of idiopathic myelofibrosis. Br J Haematol, 1994, 88(1):9-16.
5[5]D'Amato RJ,Loughnan MS,Flynn E, et al. Thalidomide is an in hibitor of angiogenesis. Proc Natl Acad Sci USA, 1994, 91 (9):4082-4085.
6[6]Giovanni B, Michelle E, Letizia C, et al. Thalidomide in myelofibrosis with myeloid metaplasia: a pooled-analysis of indi vidual patient data from five studies.Leuk Lymphoma, 2002, 43(12):2301-2307.
7[7]Piccaluga PP, Visani G, Pileri SA, et al. Clinical efficacy and antiangiogenic activity of thalidomide in myelofibrosis with myeloid metaplasia: a pilot study. Leukemia, 2002, 16 (9):1609-1614.
8[8]Elliott MA, Mesa RA,Li CY, et al. Thalidomide treatment in myelofibrosis with myeloid metaplasia. Br J Haematol, 2002, 117(2):288-296.
9[9]Mesa RA, Steensma DP, Pardanani A, et al. A phase 2 trial of combination low-dose thalidomide and prednisone for the treat ment of myelofibrosis with myeloid metaplasia. Blood, 2003, 101(7):2534-2541.
10Heis-Vahidi-Fard N, Forberg E, Eichinger S, et al. Ineffectiveness of interferon-gamma in the treatment of idiopathic myelofibrosis: a pilot study[J]. Ann Hematol,2001,80(2) :79-82.
